Real-world data presented at the 2024 EHA Congress revealed at a median follow-up of 15.5 months (range, 3.4-18.8), a heavily pretreated population of patients with relapsed/refractory multiple myeloma administered elranatamab (n = 101) achieved an overall response rate (ORR) of 51.5%, including a very good partial response (VGPR) or better rate of 42%. Notably, 22% of patients experienced a VGPR or better after 1 cycle of treatment.

Additional data showed the median duration of response (DOR) was 11 months (95% CI, 8–not applicable), and 1-year DOR rate was 48% (95% CI, 31.1%-64%). The median overall survival (OS) was 10.1 months (95% CI, 6.79-13), and the 1-year OS rate was 41.9% (95% CI, 31.7%-52.1%).

Regarding safety, the rates of grade 1 and 2 cytokine release syndrome (CRS) were 35% and 10%, respectively, and no instances of grade 3 or higher CRS were reported. Grade 1, grade 2, and grade 5 immune effector cell–associated neurotoxicity syndrome occurred in 1 patient (1%) each. The rates of any-grade infections and serious grade 3 or higher infections were 49% and 24%, respectively.